Independent Review of the 50th Annual EASL

EASL15_eSymp_theme 

 EASL15_eSymp_ondemand

About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015). This program consists of four components: (1) CME Internet Symposium: EASL 2015 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on EASL 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in the EU; (3) Rapid-Fire Review of EASL 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From EASL 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The CME Internet Symposium: EASL 2015 Review will feature four HCV experts reviewing and discussing key presentations on chronic hepatitis C presented at EASL 2015. The review and discussion will focus on HCV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations; therapies in development; epidemiology; and diagnosis and clinical management of specific patient populations, including HCV/HIV co-infected and cirrhotic patients.

This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2015 and it is not sanctioned by the organizers of EASL 2015.

Back to Top   

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2015 

  • Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at EASL 2015, to improve patient care

  • Engage patients and colleagues in discussion on studies and data presented at EASL 2015 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC

Release Date: April 30, 2015

Expiration Date: April 30, 2016

Estimated time to complete the EASL 2015 Internet Symposium: 1 hour, 45 minutes 

Media: Internet

 

Back to Top

Course Director and Moderator

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas

K. Rajender Reddy, MD
Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania 

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.  

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest. 

Nezam Afdhal, MD

  • Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Springbank, Kadmon, Janssen, Abbvie, Achillion, Sandhill Scientific
  • Research Support: Merck, Vertex, Gilead, Abbvie, BMS
  • Ownership Interest:Springbank
  • Other: Editor, Journal of Viral Hepatitis
Fred Poordad, MD
  • Consulting Fees: Abbvie, Achillion, Anadys, Biolex, BI, BMS, Gilead, GSK, Globelmmune, Idenix, Merck, Novartis, Tibotec/Janssen, Theravance, Vertex
  • Fees for Non-CME/CE Services: Gilead, Kadmon, Merck, Onyx/Bayer, Genentech, GSK, Salix, Vertex
  • Research Support: Abbvie, Achillion, Anadys, Biolex, BI, BMS, Genentech, Gilead, GSK, Globelmmune, Idenix, Idera, Intercept, Janssen, Medarex, Medtronic, Merck, Novartis, Santaris, Scynexis, Vertex, ZymoGenetics

K. Rajender Reddy, MD

  • Consulting Fees: Abbive, Janssen, BMS, Merck, Gilead
  • Contracted Research: Abbive, Janssen, BMS, Merck, Gilead (to UPenn)
Mark Sulkowski, MD
  • Consulting Fees: Abbive, BMS, Janssen, Gilead, Merck
  • Contracted Research: Achillion, Abbvie, BMS, Janssen, Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top

Instructions for Participation and Credit

 

There are no fees for participating and receiving CME credit for this activity. During the period, April 30, 2015 through April 30, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10509.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

 

 

 


 

 

PIM_small

Supported by an unrestricted educational grant from Gilead Sciences Medical Affairs.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Prepare to print

Share this page:

Get link code to this page                     


Back to Top